早期蕈样肉芽肿治疗:PROCLIPI 研究结果
PROCLIPI 研究为国际前瞻性数据库分析,纳入 17 国 41 中心共 395 例新诊断早期 MF(IA–IIA 期)患者。斑块和毛囊亲向性 MF 与选择系统治疗相关。
要点
- 早期 MF 一线以皮肤导向治疗为主,总缓解率 73%。
- 斑块和毛囊亲向性 MF 与医师选择系统治疗相关。
核心结论
- 疾病特征如斑块和毛囊亲向性 MF 影响医师治疗选择。
- 即使存在这些特征,皮肤导向治疗仍优于系统性治疗。
研究设计与样本
- PROCLIPI 为国际前瞻性数据库分析,纳入 2015 年 1 月 1 日至 2018 年 12 月 31 日 17 国 41 中心 395 例新诊断早期 MF(IA–IIA 期)患者,均经中心临床病理复核。
临床怎么用
- 早期 MF 一线优先选择皮肤导向治疗,即使存在斑块或毛囊亲向性特征。
- 系统性治疗在早期 MF 中缓解率较低,应审慎用于一线。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). OBJECTIVES: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS: In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS: The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smaller percentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS: Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.
引用
- Quaglino P, Prince HM, Cowan R, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2021. PMID: 32479678. doi:10.1111/bjd.19252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。